Comparable stake leader
TRILL AB
SEC ownership of DiaMedica Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001401040.
Disclosed value leader
Jan Stahlberg
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- DMAC on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TRILL AB
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
TRILL AB
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001401040
- Issuer location
- Minneapolis, MN
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of DiaMedica Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TRILL AB
Disclosed value leader
Jan Stahlberg
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 17%
13D/G row: TRILL AB
Showing 1-8 of 50 holder rows.
Quick read
TRILL AB leads the comparable SEC ownership view at 17%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TRILL AB's linked filing trail.
Comparable ownership
Top 5
TRILL AB
17%
TomEnterprise AB
16%
Richard Jacinto II
9.6%
Leon G. Cooperman
6.6%
Jan Stahlberg
17%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TRILL AB |
13D/G
|
17%
|
$70,252,906
8,825,742 shares
|
+$8,447,765 | 31 Dec 2025 |
| TomEnterprise AB |
13D/G
|
16%
|
$32,695,950
8,383,577 shares
|
$0 | 23 Jul 2025 |
| Richard Jacinto II |
13D/G
3/4/5
10%+ Owner
|
9.6%
|
$34,067,114
4,958,823 shares
|
$0 | 30 Sep 2025 |
| Leon G. Cooperman |
13D/G
13F
Cooperman Leon G. · Individual
|
6.6%
|
$28,462,500
3,450,000 shares
|
+$1,486,972 | 31 Dec 2025 |
| Jan Stahlberg |
3/4/5
10%+ Owner
|
17%
|
$75,679,855
8,825,742 shares
|
+$7,631,469 | 17 Nov 2025 |
| Thomas von Koch |
3/4/5
10%+ Owner
|
16%
|
$29,342,519
8,383,577 shares
|
— | 23 Jul 2025 |
| BlackRock, Inc. |
13F
Company
|
4.3%
|
$15,856,086
2,252,285 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.7%
|
$6,296,035
894,115 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$7,631,469.
Buys
$7,631,469
Insiders: 1
Sells
$0
Insiders: 0
Net
+$7,631,469
Shares: +1,061,277
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,061,277
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 1,061,277 | 0 | $7,631,469 | $0 | +$7,631,469 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to DiaMedica Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Jan Stahlberg
Net 12M change
+$7,631,469
Latest report
10 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jan Stahlberg | 10%+ Owner | $75,679,855 | +$7,631,469 | +11% | Filing P/S | 17 Nov 2025 |
| Thomas von Koch | 10%+ Owner | $29,342,519 | Filing P/S | 23 Jul 2025 | ||
| Richard Jacinto II | 10%+ Owner | $17,355,880 | Filing P/S | 23 Jul 2025 | ||
| Randall Michael Giuffre | Director | $3,727,417 | Mixed | 01 Jun 2026 | ||
| David J. Wambeke | Chief Business Officer | $3,420,969 | Mixed | 01 Jun 2025 | ||
| Richard D. Pilnik | Director | $1,440,505 | Mixed | 07 Apr 2025 | ||
| Dietrich John Pauls | President & CEO, Director | $1,098,743 | Mixed | 10 Aug 2026 | ||
| Parsons James T. | Director | $824,730 | Mixed | 01 Jun 2026 | ||
| Charles Pauling Semba | Director | $403,848 | Mixed | 01 Jun 2026 | ||
| Scott Kellen | CFO & Secretary | $209,562 | Mixed | 01 Jun 2026 | ||
| Amy L. Burroughs | Director | $205,206 | Mixed | 03 Jan 2023 | ||
| Richard Kuntz | Director | $129,332 | Mixed | 01 Jun 2026 | ||
| Harry W. Alcorn Jr. | SVP, Clinical Operations | $123,147 | Mixed | 15 Sep 2021 | ||
| Dominic R. Cundari | Chief Commercial Officer | $7,840 | Mixed | 01 Jun 2024 | ||
| Daniel J. O'Connor | Director | $0 | Mixed | 01 Jun 2026 | ||
| Tanya Lewis | Director | $0 | Mixed | 01 Jun 2026 | ||
| Julie Krop | Chief Medical Officer | Mixed | 01 Jun 2026 | |||
| Sydney A. Gilman | VP, Regulatory Affairs | Mixed | 28 Jul 2021 | |||
| Masuoka K. Lorianne | Chief Medical Officer | Mixed | 22 Jan 2024 | |||
| Kirsten L. Gruis | Chief Medical Officer | Mixed | 01 Jun 2023 |
Recent insider transactions for DiaMedica Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dietrich John Pauls | DMAC | Voting Common Shares, no par value per share | Award | 87.8% | 60,200 | 128,791 | 10 Aug 2026 | Direct | ||
| Randall Michael Giuffre | DMAC | Stock Option (right to buy) | Award | 40,412 | 40,412 | 01 Jun 2026 | Direct | |||
| Richard Kuntz | DMAC | Stock Option (right to buy) | Award | 40,412 | 40,412 | 01 Jun 2026 | Direct | |||
| Daniel J. O'Connor | DMAC | Stock Option (right to buy) | Award | 40,412 | 40,412 | 01 Jun 2026 | Direct | |||
| Tanya Lewis | DMAC | Stock Option (right to buy) | Award | 40,412 | 40,412 | 01 Jun 2026 | Direct | |||
| Charles Pauling Semba | DMAC | Stock Option (right to buy) | Award | 40,412 | 40,412 | 01 Jun 2026 | Direct | |||
| Parsons James T. | DMAC | Stock Option (right to buy) | Award | 51,189 | 51,189 | 01 Jun 2026 | Direct | |||
| Dietrich John Pauls | DMAC | Stock Option (right to buy) | Award | 380,000 | 380,000 | 01 Jun 2026 | Direct | |||
| Scott Kellen | DMAC | Stock Option (right to buy) | Award | 162,000 | 162,000 | 01 Jun 2026 | Direct | |||
| Julie Krop | DMAC | Stock Option (right to buy) | Award | 67,500 | 67,500 | 01 Jun 2026 | Direct | |||
| Parsons James T. | DMAC | Common Stock | Award | 11.5% | 10,095 | 97,949 | 02 Jan 2026 | Direct | ||
| Randall Michael Giuffre | DMAC | Common Stock | Award | 1.57% | 6,175 | 398,587 | 02 Jan 2026 | Direct | ||
| Charles Pauling Semba | DMAC | Common Stock | Award | 7.52% | 3,355 | 47,963 | 02 Jan 2026 | Direct | ||
| Jan Stahlberg | DMAC | Common Shares | Purchase | 0.84% | $626,817 | $8.57 | 73,099 | 8,825,742 | 25 Nov 2025 | See Footnote |
| Jan Stahlberg | DMAC | Common Shares | Purchase | 0.46% | $317,721 | $7.89 | 40,253 | 8,752,643 | 24 Nov 2025 | See Footnote |
| Jan Stahlberg | DMAC | Common Shares | Purchase | 2.46% | $1,547,574 | $7.41 | 208,872 | 8,712,390 | 21 Nov 2025 | See Footnote |
| Parsons James T. | DMAC | Common Stock | Options Exercise | 15.8% | 12,000 | 87,854 | 21 Nov 2025 | Direct | ||
| Parsons James T. | DMAC | Stock Option (right to buy) | Options Exercise | -100% | -12,000 | 0 | 21 Nov 2025 | Direct | ||
| Jan Stahlberg | DMAC | Common Shares | Purchase | 1.53% | $951,213 | $7.41 | 128,426 | 8,503,518 | 20 Nov 2025 | See Footnote |
| Jan Stahlberg | DMAC | Common Shares | Purchase | 2.95% | $1,732,361 | $7.21 | 240,352 | 8,375,092 | 19 Nov 2025 | See Footnote |
| Jan Stahlberg | DMAC | Common Shares | Purchase | 2.3% | $1,234,618 | $6.75 | 182,882 | 8,134,740 | 18 Nov 2025 | See Footnote |
| Jan Stahlberg | DMAC | Common Shares | Purchase | 2.41% | $1,221,165 | $6.52 | 187,393 | 7,951,858 | 17 Nov 2025 | See Footnote |
* marks a reported price that did not pass the local price check.